Mechanisms of development of antipsychotic-induced metabolic disorders: pharmacogenetic aspect
Antipsychotics are the main drug group in the treatment of disorders of the schizophrenic spectrum. At the same time, this drug group requires long-term use, has a narrow therapeutic breadth and a large spectrum and high severity of undesirable drug reactions, the manifestation of which is largely d...
Saved in:
| Main Authors: | R. F. Nasyrova, M. Yu. Tolmachev, D. A. Sychev, K. K. Yakhin, N. G. Neznanov |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Siberian State Medical University (Tomsk)
2018-01-01
|
| Series: | Бюллетень сибирской медицины |
| Subjects: | |
| Online Access: | https://bulletin.ssmu.ru/jour/article/view/1022 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacogenetic markers of antipsychotic-induced weight gain: leptin and neuroepeptide Y
by: V. S. Dobrodeeva, et al.
Published: (2021-04-01) -
Pharmacogenetics of antipsychotic-induced metabolic disturbances: state-of-the-art
by: R. F. Nasyrova, et al.
Published: (2018-07-01) -
Pharmacogenetics of carbamazepine
by: N. A. Shnayder, et al.
Published: (2020-01-01) -
Pharmacogenetics biomarkers of antipsychotics’ safety in adolescents with acute psychotic episode
by: D. V. Ivashchenko, et al.
Published: (2019-12-01) -
Pharmacogenetics of schizophrenia in real clinical practice: a clinical case
by: R. F. Nasyrova, et al.
Published: (2018-12-01)